Replies to post #236707 on Avid Bioservices Inc (CDMO)

[biopharm]

How long has Greg Lemke been working with PS Targeting?

Did anyone at Ronin group approach Greg Lemke yet? ....I think Ronin finally sees the light next week and opens up about how astronomical PS Targeting will be

REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYLSERINE

Application number: 20150164800
Abstract: The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidylserine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.

Type: Application
Filed: July 23, 2013
Issued: June 18, 2015
Assignees: Xetrios Therapeutics, Inc., Salk Institute For Biological Studies
Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt Vollrath, Carla V. Rothlin

http://patents.justia.com/inventor/lawrence-c-fritz